February 21, 2025

Lung-MAP 3.0: Simplifying the Process to Meet Patients’ Needs

The Lung Cancer Master Protocol (Lung-MAP) is an innovative clinical trial designed to efficiently address the unmet needs of patients with advanced non–small cell lung cancer (NSCLC) following front-...

The ASCO Post

February 18, 2025

Comprehensive CT Scans May Help to Identify Atherosclerosis Among Patients With Lung Cancer

Several cardiovascular risk factors may be prevalent among patients with lung cancer at the time of diagnosis and may increase their risk of future cardiovascular disease, according to findings presen...

The ASCO Post

February 14, 2025

eNRGy Trial: Zenocutuzumab for NRG1 Gene Fusion–Positive Solid Tumors

Treatment with the HER2 × HER3 bispecific antibody zenocutuzumab-zbco appeared to be safe and active in patients with advanced NRG1 gene fusion–positive solid tumors.

The ASCO Post

February 12, 2025

Mobocertinib vs Platinum-Based Chemotherapy in First-Line Treatment of EGFR Exon 20 Insertion–Positive Metastatic NSCLC

As reported in the Journal of Clinical Oncology by Jänne et al, interim analysis of the phase III EXCLAIM-2 trial showed no progression-free survival benefit with mobocertinib compared with platinum-b...

The ASCO Post

February 12, 2025

Forty-Minute Point-of-Care Lung Cancer Test

Biosensor enables early detection of lung cancer biomarkers

The Pathologist

January 29, 2025

Neoadjuvant Nivolumab/Ipilimumab vs Chemotherapy in Resectable NSCLC

In the phase III CheckMate 816 trial reported in the Journal of Clinical Oncology by Awad et al, researchers reported an exploratory analysis of the comparison of neoadjuvant nivolumab/ipilimumab vs c...

The ASCO Post

January 12, 2024

Changing Medical Practice Through Translational Research Successes

Converting data and science into medical progress requires a strategic emphasis on work that matters to patients, either through imminent application to clinical practice or potentially transformative basic discoveries.

Cedars-Sinai Pulse

December 11, 2023

Antibody-Drug Conjugate Makes Progress as Second-Line Therapy for Advanced NSCLC

Datopotamab deruxtecan (Dato-DXd), a TROP-2–directed antibody-drug conjugate, improved progression-free survival by 25% on blinded independent committee review in previously treated patients with adva...

The ASCO Post

February 24, 2023

Updated Results From the ADAURA Trial: Continued Disease-Free Survival Benefit With Adjuvant Osimertinib vs Placebo in EGFR-Mutated Stage IB–IIIA NSCLC

As reported in the Journal of Clinical Oncology by Roy S. Herbst, MD, PhD, of Yale Cancer Center and Yale School of Medicine, and colleagues, updated findings in the phase III ADAURA trial showed cont...

The ASCO Post